gvtcx

CM/PHR/22/5686- NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer

NHS England Published 3 Apr 2024 Find a Tender
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£624,000,000
Statuscomplete
Category (CPV) 33600000
Deadline1 Dec 2023
Procedureopen
OCIDocds-h6vhtk-040faf

Awards (6)

This procurement was awarded to 6 suppliers. Values shown are per-award; the notice total is £624,000,000.

SupplierValueDateStatus
Baxter Healthcare Ltd shared · · active
ITH Pharma shared · · active
LloydsPharmacy Clinical Homecare shared · · active
Qualasept Ltd t/a Bath ASU shared · · active
Quantum Pharmaceutical shared · · active
Sciensus Pharma Services Limited shared · · active

description

Proposed NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5)<br/>Tender Reference: CM/PHR/22/5686/01<br/> <br/>Period of framework agreement: 1 April 2024 to 31 March 2028 (covering regions East of England, London, North of England and South East).

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
27 Oct 2023 Contract notice (F02) Earlier regulations 031801-2023
3 Apr 2024 Contract award notice (F03) Earlier regulations 010730-2024

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.